Srinivas Akkaraju - Feb 9, 2023 Form 3 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Director, 10%+ Owner
Signature
/s/ Srinivas Akkaraju
Stock symbol
MLYS
Transactions as of
Feb 9, 2023
Transactions value $
$0
Form type
3
Date filed
2/9/2023, 06:52 PM
Previous filing
Sep 23, 2022
Next filing
Feb 16, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MLYS Series A Preferred Stock Feb 9, 2023 Common Stock 2.14M See footnote F1, F2
holding MLYS Series B Preferred Stock Feb 9, 2023 Common Stock 1.45M See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of preferred stock of the Issuer is convertible into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) at any time. The preferred stock will automatically convert into common stock upon closing of the Issuer's public offering.
F2 Represents securities held directly by Samsara BioCapital, L.P. Samsara BioCapital GP, LLC (Samsara LLC) is the general partner of Samsara BioCapital, L.P. (Samsara LP) and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein.

Remarks:

EXHIBIT LIST: EX-24 Srinivas Akkaraju POA